You just read:

Janssen's Tremfya (guselkumab) Makes its Debut in the Psoriasis Market and Early Dermatologist Feedback Reveals that Distinction from Stelara and the IL-17 Inhibitors will be Key to Success

News provided by

Spherix Global Insights

Aug 09, 2017, 16:55 ET